Fig 1.
Originally 617 patients with methicillin-sensitive Staphylococcus aureus bacteraemia (SAB) were identified. Patients with methicillin-resistant SAB were not included in the study. Patients were divided according to anti-staphylococcal penicillin (cloxacillin) or cephalosporin (cefuroxime or ceftriaxone) therapy during the 1st week. 1 Carbapenemes, Clindamycin, Vancomycin or Piperasillin-Tazobactam 2 Cefuroxime or ceftriaxone 3 Cloxacillin
Table 1.
Patient characteristics, severity of illness, treatment management and outcome of 580 patients with methicillin-sensitive Staphylococcus aureus bacteraemia (SAB).
Patients are categorised according to first week antimicrobial therapy into anti-staphylococcal penicillin or cephalosporin. Values are n (%). NS = non-significant.
Table 2.
Univariate analysis of prognostic factors for 28- and 90-days mortality in 580 patients with methicillin-sensitive Staphylococcus aureus bacteremia.
Values are expressed as N (%). NS = non-significant.
Fig 2.
Kaplan-Meier interpretation of 90 days outcome in 580 methicillin-sensitive Staphylococcus aureus bacteremia patients receiving either anti-staphylococcal penicillin (ASP, cloxacillin) (n = 488) or cephalosporin (cefuroxime or ceftriaxone) (n = 92) as first week antibiotic treatment after positive blood cultures.
Log-rank non-significant.
Table 3.
Propensity-score adjusted Cox proportional regression analysis for 28-days mortality among 580 patients with methicillin-sensitive Staphylococcus aureus bacteremia receiving either anti-staphylococcal penicillin (n = 92) or cephalosporin (n = 488) as first week antimicrobial treatment.
Table 4.
Propensity-score adjusted Cox proportional regression analysis for 90-day mortality among 580 patients with methicillin-sensitive Staphylococcus aureus bacteremia receiving either anti-staphylococcal penicillin (n = 92) or cephalosporin (n = 488) as first week antimicrobial treatment.